UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 6-K
------------
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
September 16, 2008
------------
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
NOVO ALLE
DK-2880, BAGSVAERD
DENMARK
(Address of principal executive offices)
------------
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____________________
TRANSACTION IN OWN SHARES
NOVO NORDISK A/S - SHARE REPURCHASE PROGRAMME
On 15 August 2008 Novo Nordisk initiated its share repurchase programme in
accordance with the provisions of the European Commission's regulation no
2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an amount of up to
DKK 1.7 billion in the period from 15 August 2008 to 19 December 2008.
Since the announcement as of 8 September 2008, the following transactions have
been made under the programme:
AVERAGE TRANSACTION
NUMBER OF PURCHASE PRICE VALUE, DKK
SHARES
ACCUMULATED, LAST
ANNOUNCEMENT 850,000 249,283,476
08 September 2008 50,000 278.2200 13,911,000
09 September 2008 65,000 278.2500 18,086,250
10 September 2008 90,000 278.2950 25,046,550
11 September 2008 50,000 271.3650 13,568,250
12 September 2008 50,000 273.6200 13,681,000
ACCUMULATED UNDER
THE PROGRAMME 1,155,000 333,576,526
With the transactions stated above, Novo Nordisk owns a total of 22,367,960
treasury shares, corresponding to 3.5% of the share capital. The total amount of
shares in the company is 634,000,000 including treasury shares.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 26,300 employees in
80 countries, and markets its products in 179 countries. Novo Nordisk's B shares
are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed
on the New York Stock Exchange under the symbol 'NVO'. For more information,
visit novonordisk.com.
Further information:
Media: Investors:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
------------------- --------------------
Hans Rommer
Tel: (+45) 4442 4765
hrmm@novonordisk.com
--------------------
In North America:
Sean Clements
Tel: (+1) 609 514 8316
secl@novonordisk.com
--------------------
Company Announcement no 59 / 2008
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf of the
undersigned, thereunto duly authorized.
Date: September 16, 2008 NOVO NORDISK A/S
---------------------------------------------------
Lars Rebien Sorensen,
President and Chief Executive Officer